130 related articles for article (PubMed ID: 12696176)
1. [A case of drug induced liver injury related pioglitazone].
Hisamochi A; Kumashiro R; Koga Y; Tanaka E; Ide T; Hino T; Murashima S; Ogata K; Kuwahara R; Koga H; Shishido S; Ueno T; Sata M; Eguchi T
Nihon Shokakibyo Gakkai Zasshi; 2003 Mar; 100(3):333-6. PubMed ID: 12696176
[No Abstract] [Full Text] [Related]
2. Hepatocellular injury in a patient receiving pioglitazone.
Maeda K
Ann Intern Med; 2001 Aug; 135(4):306. PubMed ID: 11511159
[No Abstract] [Full Text] [Related]
3. Summary for patients. Liver damage in a person taking the diabetes drug pioglitazone.
Ann Intern Med; 2002 Mar; 136(6):I65. PubMed ID: 11900516
[No Abstract] [Full Text] [Related]
4. "Did this drug cause my patient's hepatitis?" and related questions.
Nierenberg DW
Ann Intern Med; 2002 Mar; 136(6):480-3. PubMed ID: 11900502
[No Abstract] [Full Text] [Related]
5. Severe but reversible cholestatic liver injury after pioglitazone therapy.
Pinto AG; Cummings OW; Chalasani N
Ann Intern Med; 2002 Nov; 137(10):857. PubMed ID: 12435231
[No Abstract] [Full Text] [Related]
6. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.
May LD; Lefkowitch JH; Kram MT; Rubin DE
Ann Intern Med; 2002 Mar; 136(6):449-52. PubMed ID: 11900497
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity with thiazolidinediones: is it a class effect?
Scheen AJ
Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Krentz AJ; Bailey CJ; Melander A
BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
[No Abstract] [Full Text] [Related]
9. [Pioglitazone].
Kobayashi M; Iwata M; Hiratani K
Nihon Rinsho; 2002 Sep; 60 Suppl 9():429-37. PubMed ID: 12387029
[No Abstract] [Full Text] [Related]
10. What caused this patient's sudden liver dysfunction?
Porterfield LM
RN; 2001 Mar; 64(3):98. PubMed ID: 11288655
[No Abstract] [Full Text] [Related]
11. Hepatic injury due to troglitazone.
Malik AH; Prasad P; Saboorian MH; Thiele DL; Malet PF
Dig Dis Sci; 2000 Jan; 45(1):210-4. PubMed ID: 10695637
[No Abstract] [Full Text] [Related]
12. Angioneurotic edema as a side effect of pioglitazone.
Shadid S; Jensen MD
Diabetes Care; 2002 Feb; 25(2):405. PubMed ID: 11815525
[No Abstract] [Full Text] [Related]
13. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
[TBL] [Abstract][Full Text] [Related]
14. Does pioglitazone, like troglitazone, increase serum levels of lipoprotein(a) in diabetic patients?
Nagai Y; Abe T; Nomura G
Diabetes Care; 2001 Feb; 24(2):408-9. PubMed ID: 11213903
[No Abstract] [Full Text] [Related]
15. Severe but reversible hepatitis induced by troglitazone.
Schiano T; Dolehide K; Hart J; Baker AL
Dig Dis Sci; 2000 May; 45(5):1039-42. PubMed ID: 10795774
[No Abstract] [Full Text] [Related]
16. Late-onset troglitazone-induced hepatic dysfunction.
Bell DS; Ovalle F
Diabetes Care; 2000 Jan; 23(1):128-9. PubMed ID: 10857986
[No Abstract] [Full Text] [Related]
17. Substituting for troglitazone (Rezulin).
Med Lett Drugs Ther; 2000 Apr; 42(1076):36. PubMed ID: 10803176
[No Abstract] [Full Text] [Related]
18. [Meta-analysis shows: insulin sensitizer is safe for the liver].
MMW Fortschr Med; 2002 Oct; 144(40):47. PubMed ID: 12440297
[No Abstract] [Full Text] [Related]
19. FDA reviews troglitazone.
Donnelly R
Diabetes Obes Metab; 1999 Mar; 1(2):65-6. PubMed ID: 11220513
[No Abstract] [Full Text] [Related]
20. Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis.
Lenhard MJ; Funk WB
Diabetes Care; 2001 Jan; 24(1):168-9. PubMed ID: 11194222
[No Abstract] [Full Text] [Related]
[Next] [New Search]